Biosimilars initiative update

Following the Saskatchewan Biosimilars Initiative rollout in October 2022, the transition for HUMALOG (insulin lispro) was paused in December 2022 due to inadequate supply of the biosimilar, Admelog. Once the supply stabilized, the transition was resumed in October 2023.

Patients using HUMALOG 100 units/mL need to start using a biosimilar version of this insulin by March 31, 2024 in order to maintain their coverage under the Saskatchewan Drug Plan and our Group and Personal Health Plans.

Patients received notices directly from the SK Ministry of Health beginning October 2, 2023, and can be transitioned to a biosimilar by either their health care provider or their pharmacist.

A claims analysis was completed to identify Humalog claimants who have not yet switched to a biosimilar version and communications will be sent out to these plan members.